Peramivir
Antiviral
BioCryst Pharma to sell up to 5.75M new sharesBioCryst Pharma to sell up to 5.75M new shares BioCryst partner seeks peramivir approval in Japan BioCryst Pharmaceuticals Inc. said Wednesday its partner Shionogi & Co. filed for approval to market BioCryst's IV flu drug peramivir in... In this article: Peramivir, Bristol-Myers, Zimmer Holdings Inc., Revenue, Thomson Reuters, Oppenheimer & Co., The Miami Herald, and Morgan Stanley |
-
bizjournals: Local Business News | November 05, 2009
BioCryst ships 10K doses of flu drug to government
...hospitalized flu patients. The Birmingham-based biotech firm's intravenous drug peramivir has met several significant milestones recently, including the filing of an application for regulatory approval in Japan. The shipment to the U.S....
In this article: HHS, Birmingham, U.S. Food and Drug Administration, and Japan
-
Charlotte Observer | October 30, 2009
New flu drug to be tested at UNC
Peramivir works on the same principal as Tamiflu and Relenza, blocking an enzyme in flu viruses that enables it to flourish and spread, said Robert Bennett, executive director of business development and investor relations for BioCryst.
In this article: Relenza, U.S. Food and Drug Administration, Robert Bennett, Durham, Japan, and United States
-
PR Newswire: Multicultural News | November 04, 2009
BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan
...to include Taiwan. Under the terms of the agreement, BioCryst may receive future regulatory and commercial event milestone payments up to $102 million, as well as double digit royalty payments on product sales of peramivir. BioCryst retains...
In this article: Influenza, Japan, U.S. Food and Drug Administration, Taiwan, Forodesine, CTCL, Cancer, and T-cell lymphoma
-
Medical News Today | October 21, 2009
Swine Flu Treatments, Safety Issues Prompt Health Workers To Speak Out
...ill patients. Human clinical trials in the U.S. and Japan have called Peramivir safe and effective." But the FDA has not approved it. The agency has made at least a 20 exceptions, however, allowing "compassionate use" of the drug by...
In this article: H1N1, Google map, Relenza, Tamiflu, California and Nevada, Henry J. Kaiser Family Foundation, and FDA
-
PR Newswire: Financial | October 29, 2009
BioCryst Reports Third Quarter 2009 Financial Results and Provides Corporate Update
...a conclusion. In September, BioCryst was awarded a $77.2 million contract modification by the HHS to complete development of i.v. peramivir and it subsequently initiated two Phase 3 studies of i.v. peramivir for the treatment of...
In this article: HHS, Revenue, Forodesine, United States, FDA, Amortization, and Pharmaceutical
-
L.A. Times - Booster Shots | September 03, 2009
Could intravenous antivirals be a last-ditch treatment for swine flu?
...formulations of the drugs with some success. Additionally, BioCryst Pharmaceuticals of Birmingham, Ala, has been testing a third antiviral drug called peramivir, primarily in Japan. The President's Council of Advisors on Science and...
In this article: Relenza, GlaxoSmithKline, H1N1, Hodgkin's disease, Los Angeles Times, and Food and Drug Administration
-
PR Newswire: Health / Biotech | October 23, 2009
Emergency Use Authorization Granted For BioCryst's Peramivir
...has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in patients with complicated and uncomplicated influenza. BioCryst's partner, Shionogi & Co., Ltd. is currently preparing to file for...
In this article: Influenza, HHS, Pharmaceutical, U.S. Food and Drug Administration, Forodesine, CTCL, Cancer, and T-cell lymphoma
-
The Japan Times: All Stories | September 09, 2009
Shionogi eyes '10 for flu drug sale
...flu drug sale Shionogi & Co. forecast that its experimental treatment peramivir will earn annual sales of about YEN5 billion in Japan on demand from hospitals for patients critically ill with influenza, including swine flu. Shionogi plans...
In this article: Relenza, Tamiflu, Fujifilm Holdings Corp., Daiichi Sankyo Co., Osaka, Japan, Crestor, and Cholesterol
Trends
Loading...
More on Peramivir
Description from Wikipedia:
Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability.
BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies. ==Sources==
Explore everything named Peramivir...